New drug pricing scheme could politicise decisions and reduce access, says think tankBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2965 (Published 08 May 2013) Cite this as: BMJ 2013;346:f2965
- Adrian O’Dowd
The new proposed drug pricing scheme for the United Kingdom known as value based pricing could turn patients into “political pawns” and make it harder for them to get some drugs, an independent healthcare think tank has said.
The think tank, 2020health, published a report on 7 May in which it raises several concerns about the government’s plan to change the way that drugs are priced from next year.1 The report examines the implications of the new arrangements for patients.
Under the current system for pricing drugs, known as the Pharmaceutical Price Regulation Scheme (PPRS), the price of individual drugs is not controlled, but companies’ total revenue from the NHS is limited.
The new system of value based pricing, which is due to be …
Log in using your username and password
Log in through your institution
Sign up for a free trial